Literature DB >> 27465618

Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever.

Rosemary Wyber1, Ben J Boyd2, Samantha Colquhoun3, Bart J Currie4,5, Mark Engel6, Joseph Kado7, Ganesan Karthikeyan8, Mark Sullivan9, Anita Saxena8, Meru Sheel10, Andrew Steer11, Joseph Mucumbitsi12, Liesl Zühlke13, Jonathan Carapetis10,14.   

Abstract

Rheumatic fever is caused by an abnormal immune reaction to group A streptococcal infection. Secondary prophylaxis with antibiotics is recommended for people after their initial episode of rheumatic fever to prevent recurrent group A streptococcal infections, recurrences of rheumatic fever and progression to rheumatic heart disease. This secondary prophylaxis must be maintained for at least a decade after the last episode of rheumatic fever. Benzathine penicillin G is the first line antibiotic for secondary prophylaxis, delivered intramuscularly every 2 to 4 weeks. However, adherence to recommended secondary prophylaxis regimens is a global challenge. This paper outlines a consultation with global experts in rheumatic heart disease on the characteristics of benzathine penicillin G formulations which could be changed to improve adherence with secondary prophylaxis. Characteristics included dose interval, pain, administration mechanism, cold chain independence and cost. A sample target product profile for reformulated benzathine penicillin G is presented.

Entities:  

Keywords:  Benzathine; Fever; Heart; Penicillin; Prophylaxis; Rheumatic

Mesh：

Substances：

Year:  2016        PMID： 27465618     DOI： 10.1007/s13346-016-0313-z

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN： 2190-393X            Impact factor:   4.617


  26 in total

1.  Prophylaxis against group A streptococci in rheumatic fever; the use of single monthly injections of benzathine penicillin G.

Authors:  G H STOLLERMAN; J H RUSOFF; I HIRSCHFELD
Journal:  N Engl J Med       Date:  1955-05-12       Impact factor: 91.245

2.  A qualitative examination of secondary prophylaxis in rheumatic heart disease: factors influencing adherence to secondary prophylaxis in Uganda.

Authors:  Daniel M Huck; Haddy Nalubwama; Chris T Longenecker; Scott H Frank; Emmy Okello; Allison R Webel
Journal:  Glob Heart       Date:  2015-03

Review 3.  The global burden of group A streptococcal diseases.

Authors:  Jonathan R Carapetis; Andrew C Steer; E Kim Mulholland; Martin Weber
Journal:  Lancet Infect Dis       Date:  2005-11       Impact factor: 25.071

4.  The problem of compliance in rheumatic fever.

Authors:  K G Walker; D G Human; M M De Moor; K J Sprenger
Journal:  S Afr Med J       Date:  1987-12-05

Review 5.  Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease.

Authors:  Bo Remenyi; Jonathan Carapetis; Rosemary Wyber; Kathryn Taubert; Bongani M Mayosi
Journal:  Nat Rev Cardiol       Date:  2013-04-02       Impact factor: 32.419

6.  Long term follow up of rheumatic fever and predictors of severe rheumatic valvar disease in Brazilian children and adolescents.

Authors:  Z M A Meira; E M A Goulart; E A Colosimo; C C C Mota
Journal:  Heart       Date:  2005-08       Impact factor: 5.994

7.  Rheumatic Fever Programme in Samoa.

Authors:  Satupaitea Viali; Puleiala Saena; Vailogoua Futi
Journal:  N Z Med J       Date:  2011-02-11

Review 8.  Secondary prophylaxis for rheumatic fever: simple concepts, difficult delivery.

Authors:  Nigel Wilson
Journal:  World J Pediatr Congenit Heart Surg       Date:  2013-10

Review 9.  Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever?

Authors:  B J Currie
Journal:  Pediatrics       Date:  1996-06       Impact factor: 7.124

10.  Reducing the pain of intramuscular benzathine penicillin injections in the rheumatic fever population of Counties Manukau District Health Board.

Authors:  Kathryn Russell; Ross Nicholson; Rajeshni Naidu
Journal:  J Paediatr Child Health       Date:  2013-10-18       Impact factor: 1.954
View more
  8 in total

1.  Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD).

Authors:  Oliver D Montagnat; Graham R Webster; Jürgen B Bulitta; Cornelia Landersdorfer; Rosemary Wyber; Meru Sheel; Jonathan R Carapetis; Ben J Boyd
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

2.  Penicillin Dried Blood Spot Assay for Use in Patients Receiving Intramuscular Benzathine Penicillin G and Other Penicillin Preparations To Prevent Rheumatic Fever.

Authors:  Madhu Page-Sharp; Jonathan Coward; Brioni R Moore; Sam Salman; Lewis Marshall; Timothy M E Davis; Kevin T Batty; Laurens Manning
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

3.  Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow fibre model and mathematical modelling.

Authors:  Jessica R Tait; Timothy C Barnett; Kate E Rogers; Wee Leng Lee; Madhu Page-Sharp; Laurens Manning; Ben J Boyd; Jonathan R Carapetis; Roger L Nation; Cornelia B Landersdorfer
Journal:  J Antimicrob Chemother       Date:  2022-06-29       Impact factor: 5.758

4.  Severe adverse events following benzathine penicillin G injection for rheumatic heart disease prophylaxis: cardiac compromise more likely than anaphylaxis.

Authors:  Shannon Marantelli; Robert Hand; Jonathan Carapetis; Andrea Beaton; Rosemary Wyber
Journal:  Heart Asia       Date:  2019-06-20

5.  Adherence to Benzathine Penicillin G Secondary Prophylaxis and Its Determinants in Patients with Rheumatic Heart Disease at a Cardiac Center of an Ethiopian Tertiary Care Teaching Hospital.

Authors:  Kajela Kibirat Mekonen; Malede Berihun Yismaw; Alfoalem Araba Abiye; Tamrat Assefa Tadesse
Journal:  Patient Prefer Adherence       Date:  2020-02-19       Impact factor: 2.711

Review 6.  Rheumatic heart disease screening: Current concepts and challenges.

Authors:  Scott Dougherty; Maziar Khorsandi; Philip Herbst
Journal:  Ann Pediatr Cardiol       Date:  2017 Jan-Apr

7.  Community-Based Prescribing for Impetigo in Remote Australia: An Opportunity for Antimicrobial Stewardship.

Authors:  Stefanie Jane Oliver; James Cush; Jeanette E Ward
Journal:  Front Public Health       Date:  2017-07-12

8.  A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart disease: new insights for improved secondary prophylaxis strategies.

Authors:  Robert M Hand; Sam Salman; Nelly Newall; Julie Vine; Madhu Page-Sharp; Asha C Bowen; Katherine Gray; Amy Baker; Joseph Kado; John Joseph; Julie Marsh; James Ramsay; Dianne Sika-Paotonu; Kevin T Batty; Laurens Manning; Jonathan Carapetis
Journal:  J Antimicrob Chemother       Date:  2019-07-01       Impact factor: 5.790
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.